Skip to content
Screener

Relmada Therapeutics, Inc. RLMD Net gains (losses) on investments

Net gains (losses) on investments at other companies

Merck & Co. logo
Merck & Co.MRK
$242M+142%
Aardvark Therapeutics, Inc. logo
Aardvark Therapeutics, Inc.AARD
-$13K+13.3%
CG Oncology logo
CG OncologyCGON
-$3M-259%

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$484.28M+2,491%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.

The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055059
Line itemThree months ended / March 31, 2026Three months ended / March 31, 2025
Other income:
Interest/investment income, net959,762440,287
Realized (loss)/gain on short-term investments(9,867)62,952
Unrealized (loss)/gain on short-term investments(540,097)155,731
Total other income, net409,798658,970
Net loss$(19,051,956)$(17,559,465)
Loss per common share – basic and diluted$(0.22)$(0.58)
Weighted average number of common shares outstanding – basic and diluted86,596,87330,408,890

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Relmada Therapeutics, Inc.'s net gains (losses) on investments?
Relmada Therapeutics, Inc. (RLMD) reported net gains (losses) on investments of -$540.1K in Q1 2026.
How has Relmada Therapeutics, Inc.'s net gains (losses) on investments changed year-over-year?
Relmada Therapeutics, Inc.'s net gains (losses) on investments decreased by 446.8% year-over-year, from $155.73K to -$540.1K.
What is the long-term trend for Relmada Therapeutics, Inc.'s net gains (losses) on investments?
Over 3 years (2021 to 2025), Relmada Therapeutics, Inc.'s net gains (losses) on investments has grown at a -13.3% compound annual growth rate (CAGR), from -$611.38K to $398.25K.
What does net gains (losses) on investments mean?
Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.

Ask your AI about Relmada Therapeutics, Inc.'s net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude